The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is being challenged by the introduction of the highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of secukinumab (Novartis’s Cosentyx) has been remarkable in the first several years of its launch, but the agent faces competition from the newer, more-efficaciousIL-17 inhibitors (ixekizumab [Eli Lilly’s Taltz] and brodalumab [Bausch Health /LEO Pharma/Kyowa Hakko Kirin’s Siliq/Kyntheum/Lumicef], and IL-23 inhibitors (Janssen’sguselkumab [Tremfya] and the recently launched Merck/Sun Pharma‌ / Almirall’s tildrakizumab [Ilumya‌ / Ilumetri] and AbbVie’s risankizumab [Skyrizi]). Additionally, the landscape for the established biologics will change further with the increasing availability and use of biosimilars.

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq/ Kyntheum / Lumicef, UCB’s bimekizumab), and where are/will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of the IL-23 inhibitors (guselkumab, tildrakizumab, risankizumab, Eli Lilly’s mirikizumab), and how will they fare in the competitive psoriasis market?
  • How is the oral agent apremilast (Celgene’s Otezla) used for psoriasis treatment, and what are the other promising emerging oral therapies?
  • How fast will the uptake of biosimilars occur in psoriasis, and which brands will experience the most erosion in patient share and sales?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 20 country-specific interviews with thought leaders.

Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of psoriasis; number of diagnosed prevalent cases of psoriasis by severity.

Emerging therapies: Phase II: 14drugs; Phase III/preregistration: 7 drugs; coverage of select preclinical and Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • August 2019
      • July 2019
      • October 2018
      • August 2018
      • June 2018
      • November 2017
      • September 2017
      • May 2017
      • March 2017
      • February 2017
        • Expert Analysis: Inflectra's impact on U.S. immune markets
        • Expert Analysis: NOR-SWITCH data impact on U.S. uptake of Inflectra
    • Market Outlook
      • Key Findings
        • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Psoriasis?
        • What Factors Are Constraining the Market for Psoriasis?
      • Drug-Class-Specific Trends
        • Tumor Necrosis Factor-Alpha Inhibitors
        • IL-12/23 Inhibitors
        • IL-17 Inhibitors
        • IL-23 Inhibitors
        • PDE4 Inhibitors
        • A3AR Inhibitors
        • Select Topical Agents
        • TYK2 Inhibitors
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Disease Overview
      • Etiology
      • Pathophysiology
        • Clinical Features
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
        • Expert Insight
      • Epidemiology Populations
        • Diagnosed Prevalent Cases
        • Severity of Psoriasis
        • Diagnosed and Drug-Treated Cases of Psoriasis by Severity
    • Current Treatment Overview
      • Key Findings
      • Treatment Goals
        • Key Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • TNF-Alpha Inhibitors
        • IL-12/23 Inhibitors
        • IL-17 Inhibitors
        • IL-23 Inhibitors
        • PDE4 Inhibitors
        • Conventional Systemic Therapies
        • Topical Therapies
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Psoriasis
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments in the Late-Stage Pipeline for Psoriasis
        • IL-23 Inhibitors
        • IL-17 Inhibitors
        • A3 Adenosine Receptor Agonists
        • TYK2 Inhibitors
        • Emerging Topical Agents
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Psoriasis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Psoriasis Bibliography

Author(s): Yingdee Unhavaithaya; Devashri Mukherjee, MPH

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office. Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.


Related Reports

Psoriasis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Palmoplantar Pustular Psoriasis/Generalized Pustular Psoriasis (US )

MARKET OUTLOOK Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP])...

View Details

Psoriasis | Access and Reimbursement | US | 2018

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (

View Details

Psoriasis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbr...

View Details

Psoriasis | Emerging Therapies | Skyrizi Launch Tracking Wave 1 (US)

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (J...

View Details